Search Clinical Trials in the EU

Duration

Visits

Phase

Intake methods

Post-Trial Drug Access

Drugs

Locations

Clinical Specialty

381-400 of 847 trials

Gastro-Enteropancreatic Neuroendocrine Tumors: RYZ101 Treatment

We are studying a new treatment, RYZ101, for patients with advanced GEP-NETs that have progressed after previous therapy. The trial compares RYZ101 to standard care to see if it improves patient outcomes.

Gastroenteropancreatic Neuroendocrine TumorsConfirmation phase (III)Post-Trial Drug Access No Placebo Investigational Medicines Cost Reimbursement Partially RemoteEndocrinologyOncology

C3 Glomerulopathy: Iptacopan Study

We are studying the long-term safety and effectiveness of iptacopan for individuals with C3 glomerulopathy or idiopathic immune-complex-membranoproliferative glomerulonephritis. This research aims to understand how well the treatment works in improving kidney health.

C3 Glomerulopathy>2 yearsConfirmation phase (III)Monitoring phase (IV)11-15 visits Post-Trial Drug Access No Placebo Standard Medicines Cost ReimbursementInternal MedicineNephrology

Systemic Sclerosis-Related Lung Disease: Belimumab Study

We are investigating the long-term safety and effects of belimumab in adults with lung disease linked to systemic sclerosis. This study aims to see how the treatment impacts lung function and overall tolerability.

Lung Involvement in Systemic SclerosisBronchial Diseases>2 yearsConfirmation phase (III)11-15 visits Post-Trial Drug Access No Placebo Standard Medicines Cost ReimbursementPulmonologyRheumatology

Crohn's Disease: Vedolizumab with Upadacitinib

We are studying whether a combination of vedolizumab and upadacitinib helps improve symptoms in adults with moderately to severely active Crohn's disease compared to vedolizumab alone.

Crohn's Disease>2 yearsConfirmation phase (III)Monitoring phase (IV)6-10 visits Post-Trial Drug Access Standard Medicines Cost Reimbursement Partially RemoteGastroenterologyInternal Medicine

HIV-1 Treatment: Bictegravir/Lenacapavir for Kids and Teens

We are studying a new combination medication for children and adolescents with HIV-1 to see how well it works and how safe it is. The trial will also check if young patients find the medication easy to take.

HIV-1 Infection6-12 monthsEfficacy phase (II)Confirmation phase (III)6-10 visits Post-Trial Drug Access No Placebo Investigational Medicines Cost Reimbursement Partially RemoteInfectious DiseasesPediatrics

Volrustomig for Advanced Non-Small Cell Lung Cancer

We are studying the safety and effectiveness of volrustomig combined with chemotherapy and other drugs for patients with advanced or metastatic non-small cell lung cancer. This research aims to find better treatment options for this condition.

Non-small Cell Lung CancerSolid TumorsSQ, NSQ NSCLCEfficacy phase (II)Post-Trial Drug Access No Placebo Investigational Medicines Cost Reimbursement Partially RemoteOncology

Geographic Atrophy: Pozelimab and Cemdisiran Study

We are investigating whether a new treatment combining pozelimab with cemdisiran helps slow the progression of geographic atrophy in adults. This study aims to understand its effects on vision and safety compared to cemdisiran alone.

Geographic Atrophy from Age-Related Macular Degeneration>2 yearsConfirmation phase (III)Post-Trial Drug Access Investigational Medicines Partially RemoteInternal MedicineOphthalmology

Autoimmune Diseases: Ublituximab Administration Study

We are evaluating how well ublituximab works when given through an IV or as a subcutaneous injection in patients with autoimmune diseases. This study aims to understand the drug's effects and how it moves through the body.

Relapsing Multiple SclerosisMyasthenia Gravis1-2 yearsSafety phase (I)Post-Trial Drug Access No Placebo Standard MedicinesInternal MedicineNeurology

Guselkumab for Kids with Inflammatory Conditions

We are studying the long-term safety of guselkumab in children with ulcerative colitis, Crohn’s disease, or juvenile psoriatic arthritis. This research aims to ensure the medication is safe for young patients.

Crohn's DiseaseJuvenile Psoriatic ArthritisUlcerative Colitis1-2 yearsConfirmation phase (III)Post-Trial Drug Access No Placebo Standard Medicines Cost ReimbursementDermatologyGastroenterologyRheumatology

Non-Small Cell Lung Cancer: RMC-6236 with Pembrolizumab

We are studying a new treatment combining RMC-6236 and pembrolizumab for patients with advanced RAS-mutated non-small cell lung cancer. The goal is to evaluate its safety and potential effectiveness, with or without chemotherapy.

Non-small Cell Lung CancerSafety phase (I)>20 visits Post-Trial Drug Access No Placebo Investigational Medicines Cost ReimbursementOncologyPulmonology

Crohn's Disease: Upadacitinib for Children

We are studying the effects of Upadacitinib in children with active Crohn's disease who haven't had success with other treatments. The goal is to see if it helps them achieve better health outcomes.

Crohn's Disease>2 yearsConfirmation phase (III)11-15 visits Post-Trial Drug Access Standard Medicines Cost Reimbursement Partially RemoteGastroenterologyPediatrics

Peyronie's Disease: Study of Bacterial Collagenase

We are testing a new bacterial collagenase injection for men with Peyronie's Disease to see if it improves penile curvature and reduces discomfort. The study will assess both safety and effectiveness of this treatment.

Peyronie's Disease>2 yearsSafety phase (I)Efficacy phase (II)11-15 visits Post-Trial Drug Access No Placebo Investigational MedicinesUrology

Recurrent or Metastatic Solid Tumors: I-DXd Treatment Study

We are testing a new treatment called I-DXd for patients with recurrent or metastatic solid tumors. The study aims to see how well it works and how safe it is for participants.

Recurrent or Metastatic Solid Tumors>2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug Access No Placebo Investigational Medicines Cost ReimbursementOncology

Advanced Solid Tumors: ANV600 and Pembrolizumab Study

We are testing a new treatment, ANV600, alone and with pembrolizumab for people with advanced solid tumors. The goal is to evaluate safety and how well it may help fight cancer.

Advanced Solid Tumors>2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug Access No Placebo Investigational MedicinesOncology

Alzheimer's Disease: RO7126209 IV Treatment Study

We are investigating a new intravenous medication for individuals with mild to moderate Alzheimer's disease. The study aims to assess its safety and how it affects the brain over multiple doses.

Alzheimer's Disease>2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug Access Investigational Medicines Partially RemoteNeurologyPsychiatry

Ulcerative Colitis: Tofacitinib for Children

We are studying whether the oral medication tofacitinib can help children with moderately to severely active ulcerative colitis achieve remission. The trial will also look at how well the medication works and how it is accepted by young patients.

Ulcerative Colitis1-2 yearsConfirmation phase (III)6-10 visits Post-Trial Drug Access No Placebo Standard Medicines Cost Reimbursement Partially RemoteGastroenterologyPediatrics

Ponatinib for Pediatric Leukemias and Solid Tumors

We are studying the safety and effectiveness of ponatinib in children with recurrent or hard-to-treat leukemias and solid tumors. This trial aims to help those who have not responded to other therapies.

Acute Myeloid LeukaemiaChronic Myeloid Leukaemia1-2 yearsSafety phase (I)Efficacy phase (II)6-10 visits Post-Trial Drug Access No Placebo Standard Medicines Cost Reimbursement Partially RemoteHematologyOncology

ARO-DUX4 for Facioscapulohumeral Muscular Dystrophy Type 1

We are studying a new treatment for adults with Facioscapulohumeral Muscular Dystrophy Type 1 to see how safe it is and how it works in the body. This trial will help us understand its effects with different doses.

Facioscapulohumeral Muscular Dystrophy1-2 yearsSafety phase (I)Efficacy phase (II)6-10 visits Post-Trial Drug Access Investigational Medicines Cost ReimbursementInternal MedicineNeurology

Severe von Willebrand Disease: New Treatment Study

We are testing a new treatment for children with severe von Willebrand Disease to see if it helps control bleeding episodes and is safe during surgeries. The study will compare this treatment with and without an existing medication.

Von Willebrand's Factor Deficiency>2 yearsConfirmation phase (III)6-10 visits Post-Trial Drug Access No Placebo Standard Medicines Cost ReimbursementHematologyPediatrics

Metastatic Colorectal Cancer: Sacituzumab Govitecan Study

We are investigating a new treatment for patients with metastatic colorectal cancer who have not responded to standard care. The study aims to see if this new drug can improve survival and response rates compared to existing treatments.

Metastatic Colorectal CancerEfficacy phase (II)Confirmation phase (III)Post-Trial Drug Access No Placebo Standard MedicinesGastroenterologyOncology

Search Clinical Trials in the European Union